Safety and clinical outcomes
Among patients randomized to hAF, 2 patients (8.7%) died within 30 days, in contrast to 0 patients (0%) randomized to placebo (Comparison of safety measures by randomized treatment groupWhen restricted to patients who were not in the ICU at enrollment, changes in CRP, LDH, D-dimer and IL-6 from baseline to Day 6 were not statistically different (Table Among patients randomized to hAF who were on the floor at enrollment, 1 patient (5.9%) died within 30 days, in contrast to 0 patients (0%) randomized to placebo (When including last recorded values of biomarkers for patients who were discharged early and did not have a Day 6 value, d-dimer was more likely to have increased among patients randomized to hAF vs placebo (hAF: 0.1 (-0.1, 0.2) vs placebo: -0.1 (-0.4, 0); When restricted to patients who were not in the ICU at enrollment and had last recorded values of their biomarkers used due to being discharged early from the hospital and not having Day 6 values obtained, changes in CRP, LDH, d-dimer and IL-6 from baseline to Day 6 were not statistically different (Table 